ROIV - Roivant Sciences Ltd. Stock Price, Fair Value and News

10.37USD-0.07 (-0.67%)Market Closed

Market Summary

USD10.37-0.07

Market Closed

-0.67%

ROIV Stock Price

View Fullscreen

ROIV RSI Chart

ROIV Valuation

Market Cap

8.4B

Price/Earnings (Trailing)

1.89

Price/Sales (Trailing)

67.81

EV/EBITDA

0.48

Price/Free Cashflow

-9.97

ROIV Price/Sales (Trailing)

ROIV Profitability

EBT Margin

3461.24%

Return on Equity

72.69%

Return on Assets

60.54%

Free Cashflow Yield

-10.03%

ROIV Fundamentals

ROIV Revenue

Revenue (TTM)

123.2M

Rev. Growth (Yr)

62.63%

Rev. Growth (Qtr)

0.11%

ROIV Earnings

Earnings (TTM)

4.4B

Earnings Growth (Yr)

1.5K%

Earnings Growth (Qtr)

1.6K%

Breaking Down ROIV Revenue

Last 7 days

-7.2%

Last 30 days

4.4%

Last 90 days

0.2%

Trailing 12 Months

17.8%

How does ROIV drawdown profile look like?

ROIV Financial Health

Current Ratio

27.79

Debt/Equity

0.07

Debt/Cashflow

-2.07

ROIV Investor Care

Shares Dilution (1Y)

6.25%

Diluted EPS (TTM)

5.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	61.3M	81.9M	102.6M	123.2M
2022	55.3M	328.0M	600.7M	873.4M
2021	23.8M	30.0M	42.6M	61.2M
2020	67.7M	56.7M	45.7M	34.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Roivant Sciences Ltd.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 30, 2024	gline matthew	sold (taxes)	-2,276,550	10.54	-215,991	ceo
Mar 30, 2024	sukhatme mayukh	sold (taxes)	-3,859,860	10.54	-366,211	pres&chief investment officer
Mar 30, 2024	sukhatme mayukh	acquired	-	-	729,081	pres&chief investment officer
Mar 30, 2024	gline matthew	acquired	-	-	390,579	ceo
Mar 28, 2024	pulik richard	sold (taxes)	-24,674	10.54	-2,341	cfo
Mar 20, 2024	venker eric	sold (taxes)	-160,190	10.01	-16,003	president & coo
Mar 20, 2024	gline matthew	sold (taxes)	-109,559	10.01	-10,945	ceo
Mar 20, 2024	kumar rakhi	sold (taxes)	-15,075	10.01	-1,506	chief accounting officer
Mar 07, 2024	gold daniel allen	sold	-	-	-11,077,800	-
Mar 07, 2024	gold daniel allen	sold	-	-	-45,361	-

Which funds bought or sold ROIV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	new	-	1,581	1,581	-%
Apr 16, 2024	Edge Wealth Management LLC	reduced	-9.34	-166,696	951,003	0.20%
Apr 15, 2024	Legato Capital Management LLC	sold off	-100	-202,140	-	-%
Apr 12, 2024	DNB Asset Management AS	added	1.54	-26,853	555,310	-%
Apr 05, 2024	GAMMA Investing LLC	added	10.17	1,839	13,249	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	109	3,376	6,704	-%
Mar 11, 2024	VANGUARD GROUP INC	added	26.29	14,021,600	79,459,600	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	241	6,450,050	9,278,110	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.32	-2,856	65,729	-%

Are Funds Buying or Selling ROIV?

Are funds buying ROIV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ROIV

No. of Funds

Unveiling Roivant Sciences Ltd.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 02, 2024	sumitomo chemical co., ltd.	0.00%	0	SC 13G/A
Mar 07, 2024	qvt financial lp	8.28%	66,719,779	SC 13G/A
Feb 14, 2024	dexcel pharma technologies ltd.	0.58%	4,684,130	SC 13G/A
Feb 14, 2024	ramaswamy vivek	9.75%	81,454,521	SC 13G/A
Feb 14, 2024	qvt financial lp	13.97%	112,541,536	SC 13G/A
Feb 14, 2024	viking global investors lp	8.6%	69,368,961	SC 13G/A
Feb 13, 2024	sb investment advisers (uk) ltd	9.1%	73,031,667	SC 13G/A
Feb 13, 2024	ramaswamy vivek	9.75%	81,454,521	SC 13G/A
Feb 01, 2024	sumitomo chemical co., ltd.	8.86%	71,251,083	SC 13G/A
Jun 26, 2023	viking global investors lp	9.9%	75,238,700	SC 13G/A

Recent SEC filings of Roivant Sciences Ltd.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	3	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report
Apr 02, 2024	SC 13G/A	Major Ownership Report
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Roivant Sciences Ltd.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.83	14.44	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.02	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.43	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Roivant Sciences Ltd. News

Latest updates

Roivant Sciences Ltd. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	0.1%	37,140,000	37,101,000	21,624,000	27,376,000	22,837,750	18,299,500	13,761,250	9,223,000	24,341,000	13,987,000	7,735,000	15,146,000	5,750,000	1,323,000	-	-
Operating Expenses	3.5%	324,667,000	313,555,000	298,037,000	261,542,000	395,129,000	293,299,000	286,628,000	276,026,000	270,364,000	698,416,000	162,122,000	555,980,000	264,820,000	157,864,000	116,029,000	-
S&GA Expenses	20.0%	197,282,000	164,355,000	156,190,000	125,510,000	168,261,000	157,663,000	149,072,000	138,973,000	115,530,000	437,776,000	82,754,000	3,934,458	61,875,000	59,740,000	57,115,000	-
R&D Expenses	-6.3%	123,717,000	131,984,000	125,133,000	131,857,000	125,533,000	131,995,000	135,830,000	135,077,000	137,345,000	132,098,000	78,515,000	-121,778,000	202,261,000	97,409,000	58,734,000	-
EBITDA Margin	411.1%	35.09	-11.28	-14.65	-19.22	-1.52	-2.08	-3.54	-16.47	-	-	-	-	-	-	-	-
Interest Expenses	2.1%	9,444,000	9,247,000	8,912,000	8,575,000	8,446,000	8,335,000	2,612,000	-	-	-	-	-	-	-	-	-
Income Taxes	583.3%	25,672,000	3,757,000	1,752,000	-3,793,000	2,819,000	2,165,000	3,999,000	-163,000	38,000	401,000	93,000	19,504	-224,000	711,000	1,221,000	-
Earnings Before Taxes	1657.4%	5,098,337,000	-327,361,000	-326,093,000	-179,216,000	-382,077,000	-313,756,000	-349,785,000	-291,476,000	-306,047,000	-225,239,000	-100,985,000	19,038,604	-275,821,000	-52,787,000	-6,756,000	-
EBT Margin	392.3%	34.61	-11.84	-15.28	-19.99	-1.53	-2.10	-3.57	-16.71	-10.02	-13.68	-13.71	-13.29	-16.13	-12.26	-9.89	-8.29
Net Income	1639.1%	5,096,184,000	-331,118,000	-327,845,000	-10,464,000	-352,014,000	-315,921,000	-353,784,000	-252,035,000	-284,536,000	-225,640,000	-101,078,000	19,019,100	-261,029,000	-53,498,000	-7,977,000	-
Net Income Margin	460.8%	35.92	-9.96	-12.65	-16.65	-1.43	-1.97	-3.40	-15.61	-9.68	-13.34	-13.24	-12.75	34.53	26.25	21.17	17.74
Free Cashflow	-7.2%	-210,807,000	-196,702,000	-250,335,000	-180,710,000	-223,101,000	-192,731,000	-259,541,000	-153,732,000	-274,567,000	-123,357,000	-143,509,000	-4,327,983	-236,966,000	-99,348,000	-111,473,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q1
Assets	254.0%	7,313	2,066	2,137	2,390	2,203	2,216	2,600	2,585	2,799	3,103	2,455	2,590	413	2,477
Current Assets	338.7%	6,807	1,552	1,561	1,799	1,646	1,715	2,039	2,147	2,288	2,556	2,058	2,187	2.00	2,219
Cash Equivalents	373.7%	6,671	1,408	1,434	1,677	1,541	1,613	1,956	2,074	2,226	2,509	2,008	2,142	2,153	2,269
Net PPE	-10.7%	22.00	24.00	36.00	39.00	37.00	39.00	32.00	26.00	22.00	17.00	16.00	15.00	-	9.00
Liabilities	-1.6%	728	740	803	782	776	701	823	524	530	652	475	528	64.00	368
Current Liabilities	-7.8%	245	266	245	272	244	231	329	184	161	303	209	219	1.00	92.00
Short Term Borrowings	-	-	-	-	-	-	-	33.00	-	-	-	-	-	-	-
Long Term Debt	3.6%	403	389	385	376	375	376	384	210	172	168	155	150	-	89.00
LT Debt, Current	-6.7%	46.00	49.00	44.00	41.00	38.00	36.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	210	204	200	186	170	-	109
Shareholder's Equity	359.4%	6,090	1,326	1,334	1,158	1,427	1,514	1,755	2,039	2,247	2,428	1,957	2,040	2,171	2,086
Retained Earnings	116.6%	727	-4,368	-4,100	-3,772	-3,700	-3,387	-3,095	-2,763	-2,493	-2,200	-2,000	-1,918	-10.77	-1,109
Additional Paid-In Capital	1.3%	5,390	5,321	4,982	4,933	4,695	4,539	4,475	4,422	4,360	4,246	3,825	3,815	16.00	3,144
Shares Outstanding	0.5%	805	801	767	760	713	698	696	695	687	650	650	652	630	629
Minority Interest	31.2%	495	377	423	450	472	354	371	382	382	390	234	242	-	54.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-7.1%	-210,452	-196,427	-249,932	-179,088	-222,593	-189,630	-252,082	-147,469	-268,494	-120,596	-141,170	-237	-236,859	-98,045	-111,167	-
Share Based Compensation	10.2%	54,325	49,318	49,260	25,277	57,731	61,979	72,794	77,159	71,216	397,312	19,269	39,442	17,324	13,914	14,278	-
Cashflow From Investing	14456.4%	5,233,041	-36,451	105	113,553	-3,511	-146,852	-7,459	-5,702	-6,073	317,409	-2,339	200,284	-107	-1,864	-25,641	-
Cashflow From Financing	13.8%	236,639	207,872	7,477	210,332	154,495	-7,341	141,976	1,070	-8,422	303,934	10,210	5.00	464	175,956	181,130	-
Buy Backs	-	-	-	-	-	-	-8,329	8,329	-	-	2,247	-	-	-	-	113	-

ROIV Income Statement

2023-12-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Revenue, net	$ 37,140	$ 17,052	$ 95,865	$ 33,904
Operating expenses:
Cost of revenues	3,668	3,586	11,148	8,953
Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively)	123,717	125,533	380,834	393,358
Acquired in-process research and development	0	97,749	26,450	97,749
Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively)	197,282	168,261	517,827	474,996
Total operating expenses	324,667	395,129	936,259	975,056
Gain on sale of Telavant net assets	5,348,410	0	5,348,410	0
Income (loss) from operations	5,060,883	(378,077)	4,508,016	(941,152)
Change in fair value of investments	10,467	(25,948)	63,880	53,277
Change in fair value of debt and liability instruments	9,331	62,360	85,376	90,032
Gain on deconsolidation of subsidiaries	0	(12,514)	(17,354)	(29,276)
Interest income	(31,953)	(10,249)	(62,967)	(17,900)
Interest expense	9,444	8,446	27,603	19,393
Other income, net	(34,743)	(18,095)	(33,405)	(11,060)
Net income (loss) before income taxes	5,098,337	(382,077)	4,444,883	(1,045,618)
Income tax expense	25,672	2,819	31,181	8,983
Net income (loss)	5,072,665	(384,896)	4,413,702	(1,054,601)
Net loss attributable to noncontrolling interests	(23,519)	(32,882)	(86,339)	(79,188)
Net income (loss) attributable to Roivant Sciences Ltd.	$ 5,096,184	$ (352,014)	$ 4,500,041	$ (975,413)
Net income (loss) per common share:
Net income (loss) per common share - basic (in dollars per share)	$ 6.37	$ (0.49)	$ 5.79	$ (1.39)
Net income (loss) per common share - diluted (in dollars per share)	$ 6.03	$ (0.49)	$ 5.46	$ (1.39)
Weighted average shares outstanding:
Weighted average shares outstanding, basic (in shares)	800,587,716	713,319,399	776,759,728	703,054,773
Weighted average shares outstanding, diluted (in shares)	844,461,685	713,319,399	824,310,013	703,054,773
Product Revenue, Net [Member]
Revenues:
Revenue, net	$ 20,666	$ 9,244	$ 55,749	$ 14,354
License, Milestone and Other Revenue [Member]
Revenues:
Revenue, net	$ 16,474	$ 7,808	$ 40,116	$ 19,550

ROIV Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,670,810	$ 1,676,813
Other current assets	135,923	121,774
Total current assets	6,806,733	1,798,587
Property and equipment, net	21,857	39,086
Operating lease right-of-use assets	46,898	53,251
Investments measured at fair value	239,927	304,317
Intangible assets, net	150,415	144,881
Other assets	46,849	49,482
Total assets	7,312,679	2,389,604
Current liabilities:
Accounts payable	35,226	37,830
Accrued expenses	122,148	167,129
Operating lease liabilities	10,477	11,693
Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)	45,706	40,720
Other current liabilities	31,342	15,076
Total current liabilities	244,899	272,448
Liability instruments measured at fair value	28,374	63,546
Operating lease liabilities, noncurrent	47,059	53,476
Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)	403,337	375,515
Other liabilities	4,428	17,032
Total liabilities	728,097	782,017
Commitments and contingencies (Note 11)
Shareholders' equity:
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively	0	0
Additional paid-in capital	5,390,260	4,933,137
Retained earnings / (accumulated deficit)	727,287	(3,772,754)
Accumulated other comprehensive loss	(27,784)	(2,617)
Shareholders' equity attributable to Roivant Sciences Ltd.	6,089,763	1,157,766
Noncontrolling interests	494,819	449,821
Total shareholders' equity	6,584,582	1,607,587
Total liabilities and shareholders' equity	$ 7,312,679	$ 2,389,604

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

CEO	Mr. Matthew Gline
WEBSITE	https://roivant.com
INDUSTRY	Biotechnology
EMPLOYEES	904

Roivant Sciences Ltd. Frequently Asked Questions

What is the ticker symbol for Roivant Sciences Ltd.? What does ROIV stand for in stocks?

ROIV is the stock ticker symbol of Roivant Sciences Ltd.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Roivant Sciences Ltd. (ROIV)?

As of Thu Apr 18 2024, market cap of Roivant Sciences Ltd. is 8.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ROIV stock?

You can check ROIV's fair value in chart for subscribers.

What is the fair value of ROIV stock?

You can check ROIV's fair value in chart for subscribers. The fair value of Roivant Sciences Ltd. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Roivant Sciences Ltd. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ROIV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Roivant Sciences Ltd. a good stock to buy?

The fair value guage provides a quick view whether ROIV is over valued or under valued. Whether Roivant Sciences Ltd. is cheap or expensive depends on the assumptions which impact Roivant Sciences Ltd.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ROIV.

What is Roivant Sciences Ltd.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ROIV's PE ratio (Price to Earnings) is 1.89 and Price to Sales (PS) ratio is 67.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ROIV PE ratio will change depending on the future growth rate expectations of investors.